Category Archives: Immunology

The way to beat coronavirus (COVID-19) from testing to vaccination – ILoveQatar.net

Immunology expert Dr. Richard OKennedy, Qatar Foundation Vice President for Research, Development, and Innovation, explains how COVID-19 testing works - and why developing a vaccine takes time.

The rapid pace at which coronavirus continues to spread across the world has inevitably raised questions about testing, vaccines, and potential treatments including why testing for the virus appears difficult and time-consuming, how long a vaccine will take to develop, and how it will work once it has been developed.

Dr. Richard OKennedy, Qatar Foundation Vice President for Research, Development, and Innovation, and an immunology expert, says:

Adding to the complexity of developing accurate testing kits is the urgency with which the world is seeking these tests. However, as Dr. OKennedy points out, the companies developing them need to ensure they are validated and approved before they can move to the mass manufacturing stage, with the process rendered even more difficult due to the speed with which coronavirus (COVID-19) cases worldwide have risen:

A vaccine for coronavirus (COVID-19) has been the subject of discussion since the start of the outbreak, with such conversations often failing to recognize that the vaccine development process can take as long as 10-15 years. However, given the severity and ever-changing consequences of the current global pandemic, specialists in several countries are working around the clock on research that is aimed at developing a vaccine within a much shorter timescale.

As Dr. OKennedy explains, the immune system is essentially a series of defense mechanisms within the human body. People can play their own part in ensuring something that may look to attack their body does not have the opportunity to do so, which explains why healthcare professionals unanimously agree that the best course of action is to keep washing hands and observe social distancing guidelines.

When an infection does get through these precautions, the immune system creates antibodies to fight and counteract it. However, every so often, a virus such as the coronavirus (COVID-19) mutates and evades the human immune system.

Dr OKennedy said

A vaccine can be described as something that activates or primes the immune system. The way the polio vaccine the success rate of which has contributed to the near-elimination of polio worldwide works, for instance, is that the human immune system is exposed to a small, inactive dose of the virus to activate an immune response. This immune response allows the body to defend itself against the virus.

Dr. OKennedy said.

The consequences of prematurely introducing a vaccine that turns out to be unsafe are potentially severe. In order to prevent this, vaccines go through rigorous testing and clinical trials, contributing to the timescales involved in introducing them.

In the meantime, the global medical community is exploring potential treatments using combinations of existing drugs. One that has gained a high profile is Chloroquine, an antimalarial drug, but its effectiveness is subject to trial results.

Dr. OKennedy said:

Source: QF

Liked this article? Share it!

Excerpt from:
The way to beat coronavirus (COVID-19) from testing to vaccination - ILoveQatar.net

GenScript and Avidea Technologies to Exhibit at Virtual Summit on Cancer and Immunology Research – P&T Community

PISCATAWAY, N.J., May 7, 2020 /PRNewswire/ -- GenScript USA announced today it is collaborating with Avidea Technologieson a presentation at the SelectScience Virtual Summit on Cancer and Immunology Research 2020, taking place May 11-13.GenScript will showcase the company's Neoantigen Peptide Synthesis Services as part of Avidea Technologies' virtual presentation on personalized cancer vaccines based on self-assembling nanoparticles (SNAP) for inducing anticancer T cell immunity (Lynn et al. Nat Biotech, 2020). The presentation by Avidea Technologies' CEO Geoffrey Lynn, Ph.D. will take place May 11 at 8:45 a.m. EDT.

GenScript will also be presenting its neoantigen peptide synthesis service with partners at future virtual events, such as Oligonucleotide and Peptide Therapeutics (TIDES), LabRoots Immuno-Oncology 2020, and Protein Engineering and Cell and Gene Therapy Summit (PEGS).

"With social distancing measures, meetings like these are as critical as ever to enabling the dissemination of scientific findings and exchange of ideas that fuel innovation," Lynn said. "I'm looking forward to attending the Virtual Summit to catch-up on the latest advances in Immuno-Oncology and to discuss Avidea's own work utilizing GenScript's neoantigen peptide synthesis service to systematically develop a personalized cancer vaccine. Our findings have broad implications for the development and deployment of T cell-based immunotherapies, and I'm excited to discuss this work with attendees."

As the spread of COVID-19 forces the postponement of key scientific events, this new Virtual Summitoffers a forum for scientists and manufacturers to continue to connect to advance science.Hosted by leading science publisher SelectScience, scientists and scientific manufacturers will be joining the online event from across the world to explore headline topics including immunology and COVID-19, CAR T-cell therapy, immunotherapy, genomic research and CRISPR technology, cancer diagnostics, liquid biopsies, cancer imaging, drug delivery mechanisms, the microbiome and more.

The Summit will reach 1 million+ scientists, researchers and lab directors globally, and feature presentations by top scientists and technology innovators, workshops, video interviews, virtual resource hubs, video interviews, the latest product and application news, as well as live-chat opportunities. The Summit will be open daily from May 11-13, 2020, and interested participants may register for free here.

For more information on GenScript's neoantigen peptide synthesis services, please visit http://www.genscript.com/neoantigen-peptide-service.html.

About GenScript

GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody reagents globally. Since its founding in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. GenScript provides life science services and products to scientists in over 100 countries worldwide. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology all with the goal to Make Research Easy. For more information, visit http://www.genscript.com.

Contact:

CorporateEric Wang, vice president of marketingGenScript(732) 885-9188 ext. 131ericw@genscript.com

MediaSusan ThomasPrincipal, Endpoint Communications(619) 540-9195susan@endpointcommunications.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/genscript-and-avidea-technologies-to-exhibit-at-virtual-summit-on-cancer-and-immunology-research-301054589.html

SOURCE Genscript Biotech Corporation

Continue reading here:
GenScript and Avidea Technologies to Exhibit at Virtual Summit on Cancer and Immunology Research - P&T Community

AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study…

Paris, 7 May 2020, 6.45pm

The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma to be delivered as a late breaking oral presentation

AB Science SA (Euronext - FR0010557264 - AB) today announced that an abstract reporting findings from its Phase 3 AB07015 study on severe asthma uncontrolled by oral corticosteroids, has been selected for an oral platform presentation at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) 2020 Congress, which this year will be held digitally June 6-8, 2020.

Lavinia Davidescu (MD, PhD), Professor of Pulmonology at the University of Oradea, Romania, and coordinating investigator of study AB07015, will present key data from this positive Phase 3 trial as part of a Late Breaking Oral Abstract Session entitled Allergy Diagnosis and Asthma.

EAACI is one of the most prestigious academic meetings for pulmonary medicine and the worlds largest congress specializing in the field of allergy and clinical immunology. The Annual Congress regularly attracts 7,000-8,000 participants and experts from across the globe. Due to the current COVID-19 pandemic, EAACI will deliver the Annual Congress 2020 as a digital event consisting of pre-recorded content available beginning June 6, 2020 on the EAACI website.

Presented abstract texts will also be published on the EAACI Media Library and in the official EAACI journal Allergy after the congress.

Professor Lavinia Davidescu said: Unlike other drugs for severe asthma, masitinib targets the dual mechanisms of mast cell-related asthma pathophysiology and PDGFR-related airway remodeling. Selection of this abstract for a late breaking oral presentation at the upcoming Digital 2020 EAACI Congress is an indication of the interest being generated by this innovative approach and masitinibs potential impact on the treatment paradigm for severe asthma.

Olivier Hermine (President of the Scientific Committee of AB Science and member of the Acadmie des Sciences in France) said: Biologics for severe asthma are typically only effective in patients with a high eosinophil count of greater than 300 cells/L. In contrast, masitinib is effective across a broad population, regardless of the eosinophil level, and may therefore provide a new treatment option for biologic-ineligible patients or patients in failure to biologics.

Details for the presentation are as follows:Presentation Title: Efficacy and Safety of Masitinib in Severe Asthma: Eosinophilic Subgroup Analysis from Study AB07015Session Title: Allergy Diagnosis and Asthma: Late Breaking Oral Abstract Session (LB OAS) Late Breaking Clinical TrialsDate: Pre-recorded digital content will be available beginning June 6, 2020 at 9:00 am CEST on the EAACI website

Detailed results will be presented during the conference with an emphasis on data from a key predefined subgroup analysis in patients with initial eosinophil count of at least 150 cells/L. It is the policy of the EAACI that all scientific research-related content included in an abstract to be presented at the EAACI Digital Congress be withheld until after the abstract has been presented.

Masitinib has a unique positioning in severe asthma, in terms of administration (oral administration), mechanism of action, targeted population, and broad eosinophil level.

Masitinib is a first in class oral drug in severe asthma, selectively targeting mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN. There is a strong scientific rationale to target mast cells in asthma and study AB07015 was the first positive large-scale study in severe asthma utilizing a drug targeting mast cells [1]. Additionally, masitinib is a potent inhibitor of Platelet-Derived Growth Factor Receptor (PDGFR), which is associated with airway remodeling in asthma [2]. Masitinib is therefore capable of simultaneously modulating independent mechanisms of asthma pathophysiology, which is an attractive therapeutic strategy for severe asthma.

[1] Bradding P, Arthur G. Clin Exp Allergy. 2016 Feb;46(2):194-263.[2] Kardas G, et al. Front Pharmacol. 2020 Feb 14;11:47.

About masitinibMasitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Companys lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Sciences website: http://www.ab-science.com.

Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorit des Marchs Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB ScienceFinancial Communication & Media Relations investors@ab-science.com

Read more:
AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study...

Herd immunity in Ireland is almost impossible without a vaccine – The Irish Times

Science and in particular immunology the study of how the body fights infections is key to controlling Covid-19.

It will tell us why the virus causes severe disease in some individuals such as older people, obese people, men and diabetics and not in others.

Immunology is central to the design of vaccines and treatment approaches for a disease where the fatal outcome is a consequence of an over-active immune response to the virus.

Immunology will play a pivotal role in development and implementation of antibody testing.

It is key to decisions being made to control the Covid-19 pandemic, and it is of great concern that there is no scientist and no immunologist on the near 40-member National Public Health Emergency Team.

Most, if not all, people hospitalised for Covid-19 develop antibodies against the virus as part of the bodys immune response to the infection. People with asymptomatic infections can also develop antibodies.

Despite reports of second infections in some individuals, there is no convincing scientific evidence that an individual can be re-infected with Sars-CoV-2 and this suggests that infection induces immunity, at least in the short term.

The testing for antibodies to identify individuals previously infected with Sars-CoV-2 will serve as an important adjunct to testing for the virus. It will provide crucial epidemiological data on the prevalence of the infection in the community; studies in other countries suggest that at least 5-15 per cent of the population have been infected.

Antibody testing, with reliable assays, will also identify those who have generated an immune response to the virus and may therefore be safe to return to work.

Having antibodies against Sars-CoV-2 does not absolutely guarantee immunity from infection. However, this is the case with other viral infections and, indeed, induction of antibodies is the fundamental basis of all effective anti-viral vaccines in use today.

How close are we to a vaccine or to herd immunity?

Herd immunity is achieved when a critical threshold, usually 80-95 per cent of individuals in a target population (the herd) are rendered immune by previous infection or vaccination. It can provide protection for people who have not themselves developed immunity by eliminating the spread of the virus within the population and is particularly important in protecting the most vulnerable.

The suggestion that a level of herd immunity through Sars-CoV-2 infections is being built up in the community is not true. A community or country either has herd immunity or it does not.

A very optimistic figure of 60 per cent has been suggested as being the threshold for herd immunity against Covid-19, but this is not backed up by reproducible research findings. Estimates of 5-15 per cent of the population being infected are a long way off those required for herd immunity.

An effective vaccine is the safest and most effective means of generating herd immunity and is potentially the best medical intervention against Covid-19. More than 70 candidate Covid-19 vaccines are in development; seven of these have started the first of three phases of clinical testing. The University of Oxford Vaccine Group have predicted that they may a have a vaccine tested and ready for use in six months, but most scientists estimate it will take 12-18 months.

In order to achieve herd immunity, the entire population, including children, would have to be vaccinated. Therefore, vaccine manufacturers will have to satisfy regulatory agencies that the vaccine is not only effective but has passed stringent safety testing before it is licensed for widespread use.

Although there is no guarantee that the first vaccines will be effective, significantly, early studies in animal models are very encouraging and have suggested that certain candidate Covid-19 vaccines will be effective in humans.

How close are we to effective drugs for the treatment of Covid-19?

A huge international effort to develop drugs to control Covid-19 is ongoing.

The most promising of these is the anti-viral drug Remdesvir, which was granted an emergency use authorisation by the US Food and Drug Administration on May 1st. A report from China suggested treatment with remediation did not reduce deaths in patients with severe Covid-19. However, recent clinical trials in the US and Europe showed that the drug reduced the time of recovery from Covid-19 from 15 to 11 days.

Transfer of serum or antibodies from patients who have recovered from Covid-19 is another promising treatment approach. Plans to develop this treatment for Irish patients will be facilitated by immunology-based assays that will identify potential donors with high levels of antibodies that neutralise the virus.

In severe Covid-19, the immune systems attempt to eliminate the virus becomes uncontrolled resulting in severe inflammation in the lungs that spreads to other parts of the body. This can manifest in a syndrome called a cytokine storm. Drugs that specifically block the activity of these cytokines are another treatment option. Although the first trials have been disappointing, clinical trials with alternative drugs are ongoing.

The antimalarial drug, hydroxychloroquine and the antibiotic azithromycin are being tested on the basis of their anti-inflammatory properties, but convincing data from controlled trials is still lacking.

Recent studies from Italy have shown that the inflammation associated with Covid-19 may promote blood clots leading to lung damage that may be potentially fatal. Therefore, drugs that prevent such thrombosis are being tested and may have therapeutic benefit.

In short, drugs that slow down virus replication, suppress severe inflammation and prevent thrombosis may form part of future combination approaches to combat Covid-19 disease. Scientists and clinicians are united in their efforts to identify optimum treatment strategies before an effective vaccine is developed.

Kingston Mills is professor of experimental immunology and academic director at the Trinity Biomedical Sciences Institute, Trinity College Dublin

See the original post here:
Herd immunity in Ireland is almost impossible without a vaccine - The Irish Times

Fighting autoimmunity and cancer: The nutritional key – Science Codex

Scientists at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) revealed a novel mechanism through which the immune system can control autoimmunity and cancer. In the special focus of the researchers were regulatory T cells - a specific type of white blood cells that in general act as a brake on the immune system. The LIH research team led by Prof Dirk Brenner, FNR ATTRACT fellow and Head of Experimental & Molecular Immunology, revealed a mechanism that controls the function of regulatory T cells and determines the balance between autoimmunity and anti-cancer activity. In a preclinical model, the scientists further showed that the elucidation of the metabolic mechanism of a disease can lead to disease reduction by a rationally-designed diet that specifically addresses these metabolic alterations. This sets a new direction for future treatment of metabolic diseases. These findings, which were published today in the leading international journal Cell Metabolism, hold important implications for the development of personalised treatment options for autoimmune disorders and cancer.

"Our immune system is needed for a healthy body function and protects us from all kinds of infections. Particularly important in this respect are T cells, and specifically regulatory T cells. Although these represent only a small fraction of all T cells, they are crucial to keep our immune system in check" explains Prof Brenner. "If regulatory T cells are not functional, the immune system gets out of control and turns against its own body. This can lead to detrimental autoimmune diseases like multiple sclerosis, type I diabetes or arthritis. However, a highly reactive immune system can kill cancer cells very efficiently. This has led to the development of 'checkpoint inhibitors', specific drugs that unleash an immune system attack on cancer cells and which won the Nobel Prize in Medicine in 2018". The Luxembourgish scientists took this angle and revealed a novel mechanism by which this balance between an extreme or subdued immune reaction can be controlled by modifying regulatory T cell metabolism.

Initially, the researchers focused on how regulatory T cells cope with stress. Cellular stress can originate from the cells themselves, for example when they get activated and divide, but also from their environment, especially from nearby tumour cells. Free radicals called reactive oxygen species (ROS) are the molecular mediators of cellular stress. These are harmful for the cells and therefore need to be inactivated. "Free oxygen radicals are 'neutralised' by antioxidants and the major antioxidant in T cells is a molecule known as glutathione. We were surprised when we realised that regulatory T cells had about three times as much glutathione as other T cells. This pointed to an important function", says Henry Kurniawan, first author of the study and PhD student in Prof Brenner's group. Through a sophisticated genetic approach, the scientists removed a gene named 'glutamate cysteine ligase' (Gclc) only in a small population of regulatory T cells in mice. The Gclc gene is instrumental for glutathione production. Prof Brenner's team discovered that free radicals accumulated in these genetically altered regulatory T cells and that these cells lost their ability to act as a brake on the immune system. Strikingly, this led to a massive immune activation and a fatal autoimmune disease.

The team also found that the absence of glutathione in regulatory T cells increased serine metabolism massively. Serine is one of the 22 different amino acids that constitute the building blocks of proteins, which are in turn important for the structure and function of cells. No previous research group had studied the connection between glutathione, free radicals, serine and regulatory T cell function before. Prof Brenner's team characterised the metabolic alteration that led to the observed autoimmune disease in their mutant mice. Based on their findings, they designed a specific nutritional plan with the aim of correcting these disease-causing metabolic shifts. This dietary plan lacked both the amino acids serine and the closely related glycine. Interestingly, this engineered precision diet suppressed the severe autoimmunity and no disease developed. "Importantly, our study shows that the absence of only 2 out of 22 amino acids can cure a complex autoimmune disease. Therefore, elucidating the exact metabolic and molecular basis of a disease offers the possibility to correct these metabolic abnormalities through a special diet that is precisely adapted to the delineated disease mechanism. Our study might be a first step in the direction of the personalised treatment of metabolic diseases and autoimmunity", explains Prof Brenner.

"The relationship between glutathione, free radicals and serine can be used as a 'switch' to modulate immune cell activation. A higher immune cell activity is beneficial for cancer patients. We were intrigued by the idea of using our findings also to boost anti-tumor responses" he adds. Indeed, the team further showed that lower glutathione levels in regulatory T cells and the resulting rise in immune cell activation led to a significant tumour rejection, which might open up new therapeutic avenues for cancer treatment. "These astonishing results show the enormous potential of tweaking metabolism to prevent autoimmunity and target cancer. This could pave the way for the development of a new generation of immunotherapies," explains Prof Markus Ollert, Director of LIH's Department of Infection and Immunity. "The publication of these results in such a competitive and prestigious international journal is a momentous accomplishment not just for our department and institute, but for the entire Luxembourgish biomedical research community", he concludes.

In future projects, the researchers will use their findings to elaborate new approaches for therapeutic intervention. In that respect, the scientists have already proven that their delineated disease-controlling mechanism is also relevant in human regulatory T cells.

Due to its significance, the publication was selected by Cell Metabolism to be featured as the cover story of the May issue of the journal.

Involved research teams

Prof Dirk Brenner is the Deputy Head of Research & Strategy at LIH's Department of Infection and Immunity. He is Professor for Immunology & Genetics at the Luxembourg Center for Systems Biomedicine (LCSB) of the University of Luxembourg and Professor of Allergology at the University of Southern Denmark. He received a prestigious ATTRACT Consolidator grant from the Luxembourg National Research Fund (FNR), in 2015 to set up the Experimental & Molecular Immunology research group at LIH. The FNR-ATTRACT programme supports the national research institutions by expanding their competences in strategic research areas by attracting outstanding young researchers with high potential to Luxembourg.

The present study was performed in close collaboration with a national and international team and involved partners from LIH's Department of Infection and Immunity, LIH's Department of Oncology, the Braunschweig Integrated Center of Systems Biology (BRICS) of the Technische Universitt Braunschweig (Germany), the Helmholtz Centre for Infection Research (Germany), the Campbell Family Institute for Breast Cancer Research at the University of Toronto (Canada), the Institute for Medical Microbiology and Hospital Hygiene at the University of Marburg (Germany), the Department of Environmental Health Sciences at the Yale School of Public Health (USA), the Odense Research Center for Anaphylaxis (ORCA) of the Odense University Hospital (Denmark), the Department of Biomedical Genetics and Wilmot Cancer Institute of the University of Rochester Medical Center (USA), the Departments of Medical Biophysics and Immunology at the University of Toronto (Canada) and the University of Hong Kong (China).

View post:
Fighting autoimmunity and cancer: The nutritional key - Science Codex

Covid-19 and allergies: Allergy season gets worse every year. Heres why. – Vox.com

The weather is warming. The flowers are blooming. Noses are running. Eyes are watering.

Amid a global pandemic, many miserable Americans are asking themselves: Is it allergies or Covid-19?

The list of coronavirus symptoms continues to get longer fever, coughing, loss of smell, chills and as it does, it overlaps with other health problems even more, making it harder to know whats what. And with a shortage of Covid-19 tests, many people cant be sure whether the pollen or the virus is behind their malaise.

At the same time, its likely to be another brutal year for allergies across the United States. Texas is bracing for its worst allergy season in years. States like Georgia and New York have already seen near-record pollen counts. And in Washington, DC, pollen spiked surprisingly early this year.

If youre concerned about telling allergies apart from Covid-19, the American Academy of Allergy, Asthma, & Immunology (AAAAI) has put together a handy chart comparing their symptoms, as well as signs of the common cold and influenza:

The main symptoms common to Covid-19 but not to allergies are fever, cough, and shortness of breath. However, many people with the coronavirus dont experience any symptoms at all, and there is nothing precluding someone from having both allergies and the virus at the same time. The AAAAI says its important to continue managing allergies during the pandemic, and that its safe to use allergy control medicines like inhaled corticosteroids.

Now that its May, the US is moving away from peak tree pollen season and heading toward grass pollen season. So even more misery is in store. Grass pollen sufferers will face a long and severe season into summer, AccuWeather senior meteorologist Alan Reppert said in a report on the weather forecasters website.

Forecasters expect 2020 to be yet another above-average year for allergies, if not the worst year ever. Just like 2019, the year before that, the year before that, and the year before that.

Allergy season has become so predictably terrible that late-night comedians have taken to venting about warnings of the pollen tsunami or the pollen vortex or the perfect storm for allergies.

But it turns out theres truth behind the bombast: Pollen, an allergy trigger for one in five Americans, is surging year after year. And a major driver behind this increase is climate change.

For instance, rising average temperatures are leading to a longer ragweed pollen season, as you can see here:

A 2019 paper published in The Lancet Planetary Health journal found that airborne pollen counts have increased around the world as average temperatures climbed. The majority of the 17 sites studied showed both an increase in the amount of pollen and longer pollen seasons over 20 years.

And the faster the climate changes, the worse it gets. Thats why residents of Alaska, which is warming twice as fast as the global average, now face especially high allergy risks.

Taken together over the long term, seasonal allergies present one of the most robust examples of how global warming increases health risks. Allergies, which are already a major health burden, will become an even larger drain on the economy.

Its very strong. In fact, I think theres irrefutable data, said Jeffrey Demain, director of the Allergy, Asthma, and Immunology Center of Alaska. Its become the model of health impacts of climate change.

And since so many are afflicted some estimates say up to 50 million Americans have nasal allergies scientists and health officials are now trying to tease out the climate factors driving these risks in hopes of bringing some relief in the wake of growing pollen avalanches.

Heres what scientists have figured out so far about the relationship between climate change and seasonal allergies.

Allergies occur when the bodys internal radar system locks onto the wrong target, causing the immune system to overreact to an otherwise harmless substance.

This can cause mild annoyances like hives or itchy eyes, or life-threatening issues like anaphylaxis, where blood pressure plummets and airways start swelling shut.

About 8 percent of US adults suffer from hay fever, also known as allergic rhinitis, brought on by pollen allergies. Most cases can be treated with antihistamines, but they cost the US between $3.4 billion and $11.2 billion each year just in direct medical expenses, with a substantially higher toll from lost productivity. Complications like pollen-induced asthma attacks have also proven fatal in some instances and lead to more than 20,000 emergency room visits each year in the US.

Pollen is a fine powder produced as part of the sexual reproductive cycle of many varieties of plants, including elm trees, ryegrass, and ragweed.

Its released in response to environmental signals like temperature, precipitation, and sunlight. Grains of pollen range in size from 9 microns to 200 microns, so some types of pollen can travel deep into the lungs and cause irritation, even for people who dont have allergies. High concentrations of pollen in the air trigger allergic reactions and can spread for miles, even indoors if structures are not sealed.

There are three big peaks in pollen production throughout the year. Trees like oak, ash, birch, and maple see pollen surges in the spring. Pollen from timothy grass, bluegrass, and orchard grass peaks over the summer, and ragweed pollen spikes in the fall.

For people who are sensitive to multiple varieties of pollen, it means there will be less relief during warmer weather as these seasons overlap.

In general, pollen is emerging earlier in the year and the season is stretching out longer and longer, especially pollen from ragweed.

Ragweed is handy for studying the impacts of climate on pollen and allergies because its an annual plant, unlike trees or perennials. This allows scientists to separate out how variables like winter temperatures and rainfall in the preceding season influence ragweed pollen.

Lewis Ziska, a plant physiologist who formerly worked at the USDAs Agricultural Research Service, told Vox that the change in carbon dioxide concentrations from a preindustrial level of 280 parts per million to todays concentrations of more than 400 ppm has led to a corresponding doubling in pollen production per plant of ragweed.

How does this happen? If youve looked at a bag or bottle of plant fertilizer, you may have noticed three numbers that represent the ratio of phosphorus, nitrogen, and potassium inside. Different ratios encourage different aspects of a plants growth, like flowering or making seeds. Carbon dioxide is also an important nutrient for plants, though its not included in fertilizer (because its a gas). It turns out that higher carbon dioxide concentrations encourage plants to produce more pollen.

For ragweed, you can see a direct pollen response to increases in carbon dioxide concentrations in the atmosphere:

More pollen usually means more seeds, which means more ragweed in the next season. And warmer average temperatures mean that spring starts earlier and winter arrives later, giving pollen producers more time to spew their sneeze-inducing particles.

We can see the effects of CO2 on smaller scales as well. Researchers have found that grasses and ragweed plants increase their pollen production in response to localized surges in carbon dioxide, like from the exhaust of cars along a highway.

However, for other allergen sources like trees, the groundwork for a severe pollen season can be laid more than a year before the current season.

What happens is if the tree during the previous year has had a good season, it tends to load up on carbs so that in the spring, it has a lot of carbs to put out for flower production, Ziska said. When that happens, you can get a large bloom, and the consequences of that are inherent in the amount of pollen thats being produced.

Alaska is warming so fast that computer models have had a hard time believing the results. Thats having huge consequences for allergy sufferers in the state, and not just from pollen.

Demain from the Allergy, Asthma, and Immunology Center of Alaska explained that rising temperatures are melting permafrost beneath Alaskan towns, causing moisture to seep into homes. This dampness then allows mold to grow, causing more people to seek treatment for mold allergies.

Stinging insects are also a mounting concern. Warmer winters mean that more yellow jackets and wasps are surviving the cold months, increasing the likelihood of Alaskans getting stung. In 2006, Anchorage saw a spike in the numbers of these insects and suffered its first two deaths ever due to insect sting allergies.

It was so bad, they were canceling community outdoor events, Demain said.

Looking at patterns of people seeking medical treatment from insect stings, Demain found that the increases grew starker going northward in Alaska, with the northernmost part of the state experiencing a 626 percent increase in insect bites and stings between 2004 and 2006 compared with the period between 1999 and 2001.

Nonetheless, pollen remains a huge concern in Alaska as well, though the main source is birch trees, not ragweed. Birch pollen around Anchorage can get so bad that even people without allergies get bogged down.

For a high pollen count, you need greater than 175 grains per cubic meter, Demain said. In Alaska, we get highs between 2,000 and 4,000 grains per cubic meter.

In addition to the quantity of pollen, Demain noted that rising carbon dioxide concentrations increase the allergenic peptides on pollen. The peptides are the molecular signal that triggers the bodys immune system, so more peptides on a given pollen grain increase the severity of the allergy.

So its not just more pollen; the pollen itself is becoming more potent in causing an immune response.

For city dwellers, a big issue is that urban planners prefer to plant male trees, because they dont produce seeds, pods, or fruit that can become litter. The downside is that male trees produce pollen that can trigger allergies.

Researchers estimate that pollen counts of all varieties will double by 2040 in some parts of the country, depending on what pathway the world takes on greenhouse gas emissions. Heres how scientists project allergy risks from tree pollen will change in the eastern United States under a high greenhouse gas emissions scenario:

Heres the trajectory for ragweed:

And heres what to expect for grass pollen:

This means that regardless of your pollen of choice, the future holds more misery for allergy sufferers. And as the Covid-19 pandemic rages, it may be a long time before millions of Americans can breathe easy.

Support Voxs explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.

Read more:
Covid-19 and allergies: Allergy season gets worse every year. Heres why. - Vox.com

FTC Clears AbbVie and Allergan’s $63 Billion Merger – PharmaLive

The U.S. Federal Trade Commission gave the green light to the $63 billion mergerof AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court. A hearing is set for today.

On Tuesday, the FTC consented to the merger agreement that was initially proposed in June 2019. The FTCs consent followed approval from the European Commission, which gave a nod to the deal in March of this year. Like the previous approval from the European Commission, the FTCs consent was contingent on the divestiture of brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca. Brazikumab is currently in Phase IIb/II development for Crohns Disease and in Phase II development for ulcerative colitis. A deal for brazikumab was struck in January, along with the divestiture of two other assets, Zenpep (pancrelipase), a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, and Viokace, a pancreatic enzyme preparation, to Nestle.

In its announcement Tuesday, the FTC said it conducted a 10-month investigation into the merger and concluded that the divestitures were required in order to prevent the combined companies from having a monopoly on the treatment of various conditions.

Over the course of their 10-month investigation, commission staff explored a wide range of theories of competitive harm, including harm to innovation. They uncovered no evidence of such harm beyond those remedied by the proposed consent, the FTC said in its announcement.

Some consumer groups have raised their collective voices in opposition of the merger, claiming that the combination of AbbVie and Allergan would create a monopoly in the immunology market. Even with the divestiture of brazikumab, those in opposition, which includes unions and consumer groups, point out that the drug is still under investigation and should it fail, the divestiture will be meaningless. They also argue that AbbVie dominates the immunology market through a variety of exclusionary tactics to hamper rivals.

In addition to the divestiture of the assets, AbbVie and Allergan said that the companies amended their Transaction Agreement to allow for only one member of the Allergan Board of Directors to join AbbVies board upon closing. Allergans current chairman and chief executive officerBrent Saundershas elected not to join the AbbVie Board to provide more flexibility to pursue other opportunities in the sector.

In January, AbbVie and Allergan announced plans for a new, stand-alone company calledAllergan Aestheticsthat will include Allergans blockbuster aesthetics treatment Botox as a tent pole.

View original post here:
FTC Clears AbbVie and Allergan's $63 Billion Merger - PharmaLive

Demand for Immunology Drug Skyrockets with the Surge in Covid-19 Cases, Supporting Global Revenue 3w Market News Reports – 3rd Watch News

Given the debilitating impact of COVID-19 (Coronavirus) on the Immunology Drug market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Immunology Drug market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Analysis of the Global Immunology Drug Market

Persistence Market Research (PMR) recently published a market study which provides a detailed understanding of the various factors that are likely to influence the Immunology Drug market in the forecast period (20XX-20XX). The study demonstrates the historical and current market trends to predict the roadmap of the Immunology Drug market in the coming years. Further, the growth opportunities, capacity additions, and major limitations faced by market players in the Immunology Drug market are discussed.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15259

Regional Overview

Our team of analysts at PMR, trace the major developments within the Immunology Drug landscape in various geographies. The market share and value of each region are discussed in the report along with graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments, mergers and acquisitions of leading companies operating in the Immunology Drug market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers crucial insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

key players and products offered

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15259

Key Takeways Enclosed in the Report:

Queries Related to the Immunology Drug Market Explained:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15259

Why Opt for Persistence Market Research?

Read the original:
Demand for Immunology Drug Skyrockets with the Surge in Covid-19 Cases, Supporting Global Revenue 3w Market News Reports - 3rd Watch News

Outlook on the Artificial Immune Modulation Therapy Market to 2026 – Opportunity & Clinical Trials Insight – ResearchAndMarkets.com – Yahoo…

The "Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

The research report provides comprehensive insight on the applications of artificial immune modulation therapy in today's cancer centric treatment methodologies. This report is focused towards introducing the therapy and the cells that are contributing to the therapy in an elaborated way. The report also discusses the successful pre-clinical stage results of the therapy and information about its entry in the clinical trial landscape. The research report gives information about the growing interest of the researchers as well as companies towards the possible achievements that the therapy will face in the next few years.

Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026 Report Highlights:

Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at a global level. As every immunotherapy technology focuses on one major part of the immune system, AIM technology's working is also based on artificial antigen-presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen-presenting cells to the patients which further is projected to mimic the core functions of natural antigen-presenting cells present inside the human body.

The primary purpose with which artificial antigen-presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy-based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and the immune system.

An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of the immune system against one target which includes the activation of specific types (antigen-presenting cells and T-cells) in order to evoke a powerful immune response against a specific antigen. It has been a few decades since the development of immunotherapy for diseases in which the immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.

As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.

Key Topics Covered:

1. Artificial Immune Modulation Nanotechnology Overview

2. Role of Nanotechnology in Enriching Artificial Immune Modulation Platform

2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency

2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation

3. Synthetic Immunology to Engineer Antigen Presenting Cells

3.1 Synthetic Immunology for Already Available Immunotherapy

3.2 Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation

4. Artificial Immune Modulations for Various Indications

4.1 Immunity - Cancer Cycle Relationship

4.2 Influence of Artificial Immune Modulation Over Cancer

4.3 Influence of Artificial Immune Modulation Against Other Indications

5. T-Cell Enrichment & Expansion (E+E) Technology for Proprietary Artificial Immune Modulation Platform

6. NexImmune Clinical Trials for Artificial Immune Modulation Products

6.1 NEX-001 & NEX-003 for Acute Myeloid Leukemia

6.1.1 Overview

Story continues

6.1.2 Clinical Insight

6.2 NEX-002 for Multiple Myeloma

6.2.1 Overview

6.2.2 Clinical Insight

7. Recent Trends & Opportunities Available for Expansion of Artificial Immune Modulation Therapy

7.1 Globe Cancer Statistics

7.2 Increasing Popularity of Immunotherapy Treatments

7.3 High Adaptability by Pharmaceutical Companies

7.4 Immunotherapy in Combination with Other Cancer Treatment Methods

8. Estimated Commercial Opportunity for Artificial Immune Modulation Drugs

8.1 Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success

8.1.1 CAR-T Cell Therapy & their Products

8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy

8.2 AIM Therapy Price Estimates

9. Drivers & Challenges Triggered with the Outcome of Artificial Immune Modulation

9.1 Drivers for Artificial Immune Modulation

9.2 Challenges for Artificial Immune Modulation

10. Future Directions for Artificial Immune Modulation

10.1 Exploring New Avenues for Immunotherapy

10.2 Future Regional Landscape for Artificial Immune Modulation

11. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/5p3pd5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005450/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See original here:
Outlook on the Artificial Immune Modulation Therapy Market to 2026 - Opportunity & Clinical Trials Insight - ResearchAndMarkets.com - Yahoo...

Following the (Drug) Money – Project On Government Oversight

In an email to POGO, an aide to Murray sent a quote from the American Academy of Pediatrics (AAP) and said the group approved this quote specifically for use in your story. In the quote, Mark Del Monte, chief executive officer of the group, commended Alexander, Murray, and other lawmakers for their commitment to getting this longstanding priority across the finish line.

The CARES Act at last gives FDA the authority to safeguard public health; children will be much better off as a result, Del Monte added.

The American Academy of Pediatrics lists corporate relationships with companies such as Johnson & Johnson and GlaxoSmithKline. The organization lists in its President's Circle$50,000 and abovePampers, which is part of Procter & Gamble, maker of Pepto-Bismol and other drugstore products.

On its website, on a page titled Corporate and Organizational Partners, the American Academy of Pediatrics thanks those and other companies for their support of the Friends of Children Fund.

Through an annual membership contribution to the Fund, these companies are invited to a Corporate Summit held each summer at the AAP National Headquarters in Itasca, IL, the page says.

In response to an email from POGO, a spokesperson for the American Academy of Pediatrics, Jamie Poslosky, confirmed the quote that the Murray aide had provided. The spokesperson did not answer follow-up questions about the organizations corporate relationships.

The American Academy of Allergy, Asthma & Immunology is also a medical professionals group. In an unsigned email to POGO, the academy said its advocacy process is wholly independent, and not subject to influence by the corporate sponsors of our educational programs.

The American Academy of Allergy, Asthma & Immunology lists corporate funders such as Sanofi and GlaxoSmithKline.

Sanofis over-the-counter products include Rolaids, Selsun Blue, Aspercreme, and Dulcolax.

GlaxoSmithKline markets a variety of over-the-counter products, including Tums and Excedrin, and calls itself the number one over-the-counter respiratory medicine company.

Originally posted here:
Following the (Drug) Money - Project On Government Oversight